Classical Hodgkin Lymphoma
58
13
21
20
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
13 trials with published results (22%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
10.3%
6 terminated out of 58 trials
76.9%
-9.6% vs benchmark
7%
4 trials in Phase 3/4
65%
13 of 20 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 20 completed trials
Clinical Trials (58)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma
Phase Ib of L-NMMA and Pembrolizumab
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors
Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma
A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas